



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S):

Kornblith.

SERIAL NO:

09/039,957

GROUP NO:

1651

FILING DATE:

March 16, 1998

EXAMINER:

Gitomer, R.

TITLE:

Method for Culturing and Assaying Cells

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with the provisions of 37 C.F.R. 1.97 and 1.98, Applicants hereby make of record the publications listed on the accompanying Form PTO-1449, and other information contained herein, for consideration by the Examiner in connection with the examination of the above-identified patent application. Copies of the publications are enclosed.

REMARKS

In accordance with the provisions of 37 C.F.R. 1.97, this statement is being filed (CHECK ONE):

X	(1)	within three (3) months of the filing date of a national application other than a continued prosecution application under 37 C.F.R. 1.53(d), or within three (3) months of the date of entry of the national stage as set forth in 37 C.F.R. 1.491 in an international application, or before the mailing of the first Office action on the merits or before the mailing of a first Office action after the filing of a request for continued examination under 37 C.F.R. 1.114; or
	(2)	after the period defined in (1) but before the mailing date of a final action or a notice of allowance under 37 C.F.R. 1.311, and
		the requisite Statement is below, OR
		the requisite fee under 37 C.F.R. 1.17(p), namely \$180.00, is included herein, or

Serial No. 09/039,957 Page 2 of 2 (3) after the mailing date of a final action or notice of allowance but before the payment of the issue fee, AND the requisite Statement is below, AND the requisite petition fee under 37 C.F.R. 1.17(p), namely \$180.00 is included herein. It is respectfully requested that each of the patents and publications listed on the attached Form PTO-1449, and other information contained herein, be made of record in this application. **STATEMENT** As required under 37 C.F.R. 1.97(e), Applicant(s), through the undersigned, hereby state either that [check the appropriate space only if either (2) or (3) is checked on the previous page and the Statement is required]: Each item of information contained in the Information Disclosure Statement was 1. first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Information Disclosure Statement; or 2. No item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this Statement after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to any individual designated in 37 C.F.R. 1.56(c) more than three months prior to the filing of the Information Disclosure Statement.

Date: February 6, 2004 Reg. No. 50,794

Supplemental Information Disclosure Statement

Tel. No.: (617) 310-8158 Fax No.: (617) 248-7100

3018991

Respectfully submitted,

Jeremy R. Oczek

Attorney for Applicants


Testa, Hurwitz, & Thibeault, LLP

High Street Tower 125 High Street

Boston, Massachusetts 02110

FORM PTO - 1449					ATTORNEY DOCKET NO.: PTI-002						
SUPPLEMENTA INFORMATION DISCLOSURE				SURE	APPLICANT: Kornblith						
STATEMENT											
		FEB 0 9 2004	<u> </u>	j	SERIAL I	NO.: 09/	039,957				
•	13		<u> </u>		FILING DATE: March 16, 1998						
	4	PADENNE	U.S. 1	PATENT D	OCUME	NTS					
EXAM.		DOCUMENT	DATE NAME		CLASS			SUB FILING DATE IF			
INIT.		NUMBER						CLASS			
										<u> </u>	
					· . <u></u>			-			
						_					
				•							
FOREIGN PATENT DOCUMENTS											
EXAM.		DOCUMENT	DATE	COUNTRY	CLASS	SUB	FILING	G ABSTRACT ENGLISH			
INIT.		NUMBER		CODE		CLASS	DATE	ONLY		LANG	
. <u>.</u>										(Y/N)	
			OTHER AR	Γ, JOURNA	AL ARTIC	CLES, ET	rc.				
EXAM. INIT.											
	C23	Bosanquet, Andrew G., "Short-term In Vitro Drug Sensitivity Tests for Cancer Chemotherapy. A Summary of Correlations of Test result With Both Patient Response and Survival", Forum, vol. 4, no. 2, pp. 179-195 (1994).									
	C24	Furuehauf, J.P. "In Vitro Assay-Assisted Treatment selection for Women with Breast or Ovarian Cancer", Endocrine-Related Cancer, vol. 9, pp. 171-182 (2002).									
	C25	McGuire, William L. et al., "In Vitro Assays to Predict Drug Sensitivity and Drug Resistance", Breast Cancer Research and Treatment, vol. 12, pp. 7-21 (1988).									
	C26	Robert, Jacques, "Chemosensitivity Testing- Prediction of Response to Anticancer Drugs Using In Vitro Assays", Electronic Journal of Oncology, vol. 2, pp. 198-210 (1999).									
EXAMINER			DATE CONSIDERED								

tost B



OIPE CONTRADEMENTAL

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT:

Kornblith

SERIAL NO.:

09/039,957

GROUP NO.:

1651

FILING DATE:

March 16, 1998

EXAMINER:

Gitomer, R.

TITLE:

Method for Culturing and Assaying Cells

CERTIFICATE OF FIRST CLASS MAILING UNDER 37 C.F.R. 1.8

I hereby certify that this correspondence, and any documents referred to as enclosed herein, are being deposited with the United States Postal Service as first class mail, postage prepaid, in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on this 6th day of February, 2004

Heather Morgan

Heather Morgan

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Submitted herewith are:

- 1. Transmittal Form (1 pg.);
- 2. Supplemental Information Disclosure Statement (2 pgs.);
- 3. Form PTO-1449 (1 pg.);
- 4. Copies of References as Cited (C23-26); and
- 5. a Return Receipt Postcard.

<u> </u>	1 %	_							
·	a mak wi	Application Serial Number			09/039,957				
FER	09 2004	Filing Date		1	March 16, 1998 Kornblith 1651				
W.		First Name	d Inventor	1					
301	TRANSMITTA	Group Art	Unit						
		Examiner l	Name		Gitomer, R.				
	FORM		Attorney D	ocket No.		PTI-002			
			Patent No.		7	Not applicable			
	,		Issue Date			Not applicable			
		ENC	CLOSURES (c	heck all that apply)					
☐ Fe	e Transmittal Form		Copy of Notic	e to File Missing cation (PTO-1553)	Г	Notice of Appeal to Board of Patent Appeals and Interferences			
	☐ Check Attached ☐ Copy of Fee Transmittal Form		Formal Drawin						
	Amendment/Response		Request For C Examination (Status Inquiry			
	☐ Preliminary ☐ After Final		Transmittal		×	Return Receipt Postcard			
,	☐ Affidavits/declaration(s) ☐ Letter to Official ☐ Draftsperson including Drawings		Power of Attorney (Revocation of Prior Powers)		×	Certificate of First Class Mailing under 37 C.F.R. 1.8			
	[Total Sheets]		Terminal Disc	laimer	С	Certificate of Facsimile Transmission under 37 C.F.R. 1.8			
	Petition for Extension of Time			aration and Power r Utility or Design ttion		Additional Enclosure(s) (please identify below)			
\boxtimes	Supplemental Information Disclosure Statement		Small Entity S	tatement					
1	Form PTO-1449 Copies of IDS Citations (C23-26)	. —	CD(s) for large program	e table or computer					
	Certified Copy of Priority Document(s)		Amendment A	fter Allowance					
			Request for Certificate of Correction Certificate of Correction (in duplicate)						
CORRESPONDENCE ADDRESS				SIGNATURE BLO	оC				
Direct all correspondence to: Patent Administrator Testa, Hurwitz & Thibe High Street Tower 125 High Street Boston, MA 02110 Tel. No.: (617) 248-710 Fax No.: (617) 248-710			ibeault, LLP	Date: February 6, 20 Reg. No. 50,794 Tel. No.: (617) 310- Fax No.: (617) 248-	-81:	Jeremy D. Oczek J 58 Attorney for Applicant			